115436-72-1 | sodium hydrogen [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonate

Packsize	Purity	Availability	Price	Discounted Price
25mg	98%	in stock	$6.00	$4.00
1g	97%	in stock	$31.00	$22.00
5g	97%	in stock	$93.00	$65.00
25g	98%	in stock	$387.00	$271.00

Description

• Catalog Number: AA20528
• Chemical Name: sodium hydrogen [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonate
• CAS Number: 115436-72-1
• Molecular Formula: C7H10NNaO7P2
• Molecular Weight: 305.0941
• MDL Number: MFCD14584874
• SMILES: OC(P(=O)(O)O)(P(=O)(O)[O-])Cc1cccnc1.[Na+]

Computed Properties

• Complexity: 375
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 18
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 4
• Undefined Atom Stereocenter Count: 1

Literature

• Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).

  European journal of cancer (Oxford, England : 1990) 20121101

• Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study.

  Spine 20121101

• Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis.

  Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 20121001

• Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.

  Journal of cancer research and clinical oncology 20120901

• Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates.

  Journal of bone and mineral metabolism 20120901

• Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.

  Bone 20120901

• Risedronate-associated scleritis: a case report and review of the literature.

  Clinical rheumatology 20120901

• Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120801

• The association between automatic generic substitution and treatment persistence with oral bisphosphonates.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120801

• The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120801

• Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.

  Journal of Crohn's & colitis 20120801

• Lipid profiles within the SABRE trial of anastrozole with and without risedronate.

  Breast cancer research and treatment 20120801

• Effect of risedronate on bone in renal transplant recipients.

  Journal of the American Society of Nephrology : JASN 20120801

• Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.

  Journal of bone and mineral metabolism 20120701

• Risedronate improves bone mineral density in Crohn's disease: a complementary mechanism.

  Journal of Crohn's & colitis 20120701

• Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures?

  The Journal of bone and joint surgery. British volume 20120701

• Successful treatment of calcific uraemic arteriolopathy with bisphosphonates.

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20120514

• Long-term outcomes of children and adolescents who had cerebral palsy with secondary osteoporosis.

  Current medical research and opinion 20120501

• Effects of alendronate and risedronate on bone material properties in actively forming trabecular bone surfaces.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20120501

• Prospective evaluation of free radicals and antioxidant activity following 6-month risedronate treatment in patients with postmenopausal osteoporosis.

  Rheumatology international 20120401

• [Simultaneous determination of alendronate, pamidronate, ibandronate and risedronate using ion chromatography with integrated pulsed amperometric detection].

  Se pu = Chinese journal of chromatography 20120401

• Lipophilic analogs of zoledronate and risedronate inhibit Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and exhibit potent antimalarial activity.

  Proceedings of the National Academy of Sciences of the United States of America 20120313

• Osteoporosis, osteopenia and fracture risk: widening the therapeutic horizons.

  South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20120308

• Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120301

• Adherence to osteoporosis medications amongst Singaporean patients.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120301

• Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120301

• Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).

  Current medical research and opinion 20120301

• Paget disease of bone - an update.

  Australian family physician 20120301

• Immediate loading in mandible full-arch: pilot study in patients with osteoporosis in bisphosphonate therapy.

  The Journal of oral implantology 20120201

• Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120201

• Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20120201

• Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.

  Clinical drug investigation 20120201

• Development and validation of a sensitive solid-phase-extraction (SPE) method using high-performance liquid chromatography/tandem mass spectrometry (LC-MS/MS) for determination of risedronate concentrations in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120115

• Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120101

• Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120101

• Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120101

• Topically administered Risedronate shows powerful anti-osteoporosis effect in ovariectomized mouse model.

  Bone 20120101

• Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.

  Bone 20120101

• Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20120101

• Heel ultrasound can assess maintenance of bone mass in women with breast cancer.

  Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20120101

• Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs.

  PloS one 20120101

• Elcatonin in combination with risedronate is more effective than risedronate alone for relieving back pain in postmenopausal women with osteoporosis.

  Biological & pharmaceutical bulletin 20120101

• Atypical bilateral pedicle fracture in long-term bisphosphonate therapy.

  Spine 20111215

• Bisphosphonate treatment delays stress fracture remodeling in the rat ulna.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20111201

• The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20111201

• Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial.

  Journal of neurology, neurosurgery, and psychiatry 20111201

• Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis.

  Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 20111201

• Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.

  Bone 20111201

• Distinguishing the proapoptotic and antiresorptive functions of risedronate in murine osteoclasts: role of the Akt pathway and the ERK/Bim axis.

  Arthritis and rheumatism 20111201

• Identifying common trajectories of joint space narrowing over two years in knee osteoarthritis.

  Arthritis care & research 20111201

• Gastric ulcerogenic and healing impairment effects of risedronate, a nitrogen-containing bisphosphonate in rats. Comparison with alendronate and minodronate.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20111201

• Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20111201

• Different modalities of NaCl osmogen in biodegradable microspheres for bone deposition of risedronate sodium by alveolar targeting.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20111101

• Effect of stopping risedronate after long-term treatment on bone turnover.

  The Journal of clinical endocrinology and metabolism 20111101

• Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease.

  European journal of gastroenterology & hepatology 20111101

• Ion pairs of risedronate for transdermal delivery and enhanced permeation rate on hairless mouse skin.

  International journal of pharmaceutics 20111031

• The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial.

  The Journal of bone and joint surgery. American volume 20111019

• Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover.

  Bone 20111001

• Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.

  Journal of clinical pharmacy and therapeutics 20111001

• Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.

  Journal of managed care pharmacy : JMCP 20111001

• Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study.

  Journal of bone and mineral metabolism 20110901

• Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study.

  Prostate cancer and prostatic diseases 20110901

• Comparison of the effects of elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using SF-36.

  Journal of bone and mineral metabolism 20110901

• Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).

  Calcified tissue international 20110901

• In vitro disintegration studies of weekly generic and branded risedronate sodium formulations available in Canada.

  Current medical research and opinion 20110901

• What is the optimal duration of bisphosphonate therapy?

  Cleveland Clinic journal of medicine 20110901

• Effect of risedronate on osteoblast differentiation, expression of receptor activator of NF-κB ligand and apoptosis in mesenchymal stem cells.

  Basic & clinical pharmacology & toxicology 20110801

• Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate.

  Bone 20110701

• Hip structure analysis of bisphosphonate-treated Japanese postmenopausal women with osteoporosis.

  Journal of bone and mineral metabolism 20110701

• Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20110701

• Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study.

  Transplant international : official journal of the European Society for Organ Transplantation 20110701

• Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice.

  Bone 20110701

• Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study.

  The Journal of clinical endocrinology and metabolism 20110701

• Simultaneous bilateral subtrochanteric fractures following risedronate therapy.

  Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 20110701

• Shotgun proteomics analysis reveals new unsuspected molecular effectors of nitrogen-containing bisphosphonates in osteocytes.

  Journal of proteomics 20110610

• Effects of risedronate in Runx2 overexpressing mice, an animal model for evaluation of treatment effects on bone quality and fractures.

  Calcified tissue international 20110601

• Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis.

  Clinical endocrinology 20110601

• Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin.

  Panminerva medica 20110601

• Crystallization products of risedronate with carbohydrates and their substituted derivatives.

  Molecules (Basel, Switzerland) 20110504

• Effects of risedronate on bone marrow adipocytes in postmenopausal women.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110501

• In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum.

  Antimicrobial agents and chemotherapy 20110501

• Dose-dependent differential effects of risedronate on gene expression in osteoblasts.

  Biochemical pharmacology 20110415

• Osteoporosis medication and reduced mortality risk in elderly women and men.

  The Journal of clinical endocrinology and metabolism 20110401

• In brief: delayed-release risedronate (Atelvia).

  The Medical letter on drugs and therapeutics 20110321

• Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110301

• Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110301

• Characterization of a new solvate of risedronate.

  Journal of pharmaceutical sciences 20110301

• Effects of risedronate on cortical and trabecular bone of the mandible in glucocorticoid-treated growing rats.

  American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics 20110301

• Osteonecrosis of the jaw and the role of macrophages.

  Journal of the National Cancer Institute 20110202

• [Incidence of hip fractures due to osteoporosis in relation to the prescription of drugs for their prevention and treatment in Galicia, Spain].

  Atencion primaria 20110201

• A reliable predictive factorial model for entrapment optimization of a sodium bisphosphonate into biodegradable microspheres.

  Journal of pharmaceutical sciences 20110201

• Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.

  Bone 20110201

• Treatments for osteoporosis in people with a disability.

  PM & R : the journal of injury, function, and rehabilitation 20110201

• Risedronate improves proximal femur bone density and geometry in patients with osteoporosis or osteopenia and clinical risk factors of fractures: a practice-based observational study.

  Journal of bone and mineral metabolism 20110101

• The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer.

  Breast cancer research and treatment 20110101

• When do bisphosphonates make the most sense?

  The Journal of family practice 20110101

• A case of Marinesco-Sjögren syndrome: MRI observations of skeletal muscles, bone metabolism, and treatment with testosterone and risedronate.

  Internal medicine (Tokyo, Japan) 20110101

• [Bilateral pathological sub-trochanteric fracture in a long-term biphosphonate user].

  Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca 20110101

• Multiple vertebral compression fractures associated with post partum osteoporosis.

  Journal of back and musculoskeletal rehabilitation 20110101

• The assessment of regional skeletal metabolism: studies of osteoporosis treatments using quantitative radionuclide imaging.

  Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20110101

• The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial.

  The Kurume medical journal 20110101

• Stress fractures: diagnosis, treatment, and prevention.

  American family physician 20110101

• Going on a drug holiday?

  Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20110101

• Beneficial effect of risedronate on arterial thickening and stiffening with a reciprocal relationship to its effect on bone mass in female osteoporosis patients: a longitudinal study.

  Life sciences 20101218

• Risedronate metal complexes potentially active against Chagas disease.

  Journal of inorganic biochemistry 20101201

• Response of postpoliomyelitis patients to bisphosphonate treatment.

  PM & R : the journal of injury, function, and rehabilitation 20101201

• Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.

  Clinical breast cancer 20101201

• Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer.

  BJU international 20101101

• Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20101101

• Effect of risedronate on osteocyte viability and bone turnover in paired iliac bone biopsies from early postmenopausal women.

  Calcified tissue international 20101101

• How to prevent glucocorticoid-induced osteoporosis.

  Cleveland Clinic journal of medicine 20101101

• The effects of risedronate and exercise on osteoporotic lumbar rat vertebrae and their sensory innervation.

  Spine 20101015

• Particulate adducts based on sodium risedronate and titanium dioxide for the bioavailability enhancement of oral administered bisphosphonates.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20101009

• Novel bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase.

  Bioorganic & medicinal chemistry letters 20101001

• Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.

  Calcified tissue international 20101001

• Diagnosis of Paget's disease of the pelvis using F-18 FDG PET/CT.

  International journal of rheumatic diseases 20101001

• High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment.

  Journal of bone and mineral metabolism 20100901

• In vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat.

  Arthritis and rheumatism 20100901

• [Dementia and fracture].

  Clinical calcium 20100901

• [Jaw osteonecrosis induced by oral biphosphonates: 12 cases].

  Revue de stomatologie et de chirurgie maxillo-faciale 20100901

• The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20100801

• Histology of an undisplaced femoral fatigue fracture in association with bisphosphonate treatment. Frozen bone with remodelling at the crack.

  Acta orthopaedica 20100801

• Effect of risedronate on bone resorption during consolidation phase of distraction osteogenesis: a rabbit model.

  Journal of orthopaedic surgery (Hong Kong) 20100801

• Effects of the bisphosphonate risedronate on osteopenia in OASIS-deficient mice.

  Journal of bone and mineral metabolism 20100701

• Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget's disease of bone.

  Journal of bone and mineral metabolism 20100701

• How do bisphosphonates inhibit bone metastasis in vivo?

  Neoplasia (New York, N.Y.) 20100701

• [Osteoporosis management in general practice. Preventing spontaneous bone fractures].

  MMW Fortschritte der Medizin 20100701

• Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients.

  Transplantation 20100627

• Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20100601

• Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis.

  The American journal of the medical sciences 20100601

• Risedronate-induced arthritis.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20100601

• Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.

  Journal of medicinal chemistry 20100513

• Atypical femoral fractures and bisphosphonate use.

  The New England journal of medicine 20100513

• An in vitro assay to measure targeted drug delivery to bone mineral.

  ChemMedChem 20100503

• Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20100501

• How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.

  Journal of the American Dental Association (1939) 20100501

• Osteonecrosis of the jawbones in 2 osteoporosis patients treated with nitrogen-containing bisphosphonates: osteonecrosis reduction replacing NBP with non-NBP (etidronate) and rationale.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20100401

• Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.

  Aging clinical and experimental research 20100401

• Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies.

  Journal of the American Geriatrics Society 20100401

• Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20100301

• Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20100301

• The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20100301

• The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year trial.

  Bone 20100301

• Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity.

  Bone 20100301

• Effect of osteoporosis treatment on mortality: a meta-analysis.

  The Journal of clinical endocrinology and metabolism 20100301

• Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.

  Journal of women's health (2002) 20100301

• Effects of risedronate on osteoarthritis of the knee.

  Yonsei medical journal 20100301

• Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20100301

• Intravenous zoledronic acid: what are the indications for male osteoporosis?

  Current osteoporosis reports 20100301

• Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100220

• Unusual mid-shaft fractures during long-term bisphosphonate therapy.

  Clinical endocrinology 20100201

• Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.

  Bone 20100201

• Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20100201

• Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures.

  Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20100201

• A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20100101

• Risedronate reduces intracortical porosity in women with osteoporosis.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20100101

• Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice.

  Journal of bone and mineral metabolism 20100101

• Risedronate prevents early radiation-induced osteoporosis in mice at multiple skeletal locations.

  Bone 20100101

• Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.

  Bone 20100101

• Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading.

  Bone 20100101

• Differences between bisphosphonates in binding affinities for hydroxyapatite.

  Journal of biomedical materials research. Part B, Applied biomaterials 20100101

• Risedronate on 2 consecutive days a month reduced vertebral fracture risk at 1year compared with historical placebo.

  Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20100101

• Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone.

  Calcified tissue international 20100101

• [Diagnosis and treatment of osteoporosis in persons aged more than 75 years].

  Revista espanola de geriatria y gerontologia 20100101

• Response of serum carboxylated and undercarboxylated osteocalcin to risedronate monotherapy and combined therapy with vitamin K(2) in corticosteroid-treated patients: a pilot study.

  Internal medicine (Tokyo, Japan) 20100101

• Analysis of risedronate and related substances by ion-pair reversed-phase high-performance liquid chromatography with evaporative light-scattering detection.

  Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20100101

• Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.

  Breast cancer research : BCR 20100101

• Challenges in clinical patient management.

  Cancer investigation 20100101

• The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation.

  Arthritis research & therapy 20100101

• Development of an ion-pair reversed-phase HPLC method with indirect UV detection for determination of phosphates and phosphites as impurities in sodium risedronate.

  Journal of AOAC International 20100101

• Development and validation of a micellar high-performance liquid chromatographic method for determination of risedronate in raw material and in a pharmaceutical formulation: application to stability studies.

  Journal of AOAC International 20100101

• Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome.

  Internal medicine (Tokyo, Japan) 20100101

• Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.

  Rheumatology international 20091201

• Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.

  Current medical research and opinion 20091201

• Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20091201

• Review of osteoporosis pharmacotherapy for geriatric patients.

  The American journal of geriatric pharmacotherapy 20091201

• Prior treatment with vitamin K(2) significantly improves the efficacy of risedronate.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20091101

• Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20091101

• Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.

  Calcified tissue international 20091101

• A retrospective clinical and radiographic study on healing of periradicular lesions in patients taking oral bisphosphonates.

  Journal of endodontics 20091101

• Comparative gastrointestinal safety of weekly oral bisphosphonates.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20091001

• Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20091001

• Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology.

  The Journal of clinical endocrinology and metabolism 20091001

• Nanostructured polyelectrolyte multilayer drug delivery systems for bone metastasis prevention.

  Biomaterials 20091001

• Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090901

• Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790.

  International journal of cancer 20090901

• Re 'Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors' by A. Luckish et al.

  Bone 20090901

• Differences in persistence among different weekly oral bisphosphonate medications.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090801

• Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy.

  Current medical research and opinion 20090801

• [Biochemical markers of bone turnover. New aspect. Biochemical markers of bone turnover in long term treatment with bisphosphonate].

  Clinical calcium 20090801

• Corticosteroids: no drug prevention of fractures needed.

  Prescrire international 20090801

• Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.

  La Tunisie medicale 20090801

• Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats.

  Maturitas 20090720

• Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20090701

• Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss.

  Biological & pharmaceutical bulletin 20090701

• [Acute exacerbation of a chronic esophagitis].

  Deutsche medizinische Wochenschrift (1946) 20090701

• DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090601

• Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090601

• RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090601

• Bone microdamage.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090601

• Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy.

  Urology 20090601

• Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20090601

• Synergistic action of statins and nitrogen-containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblasts.

  The Journal of pharmacy and pharmacology 20090601

• Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.

  La Tunisie medicale 20090601

• Theoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage.

  Journal of biomechanics 20090511

• Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.

  Bone 20090501

• Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.

  Southern medical journal 20090501

• Osteonecrosis associated with short-term oral administration of bisphosphonate.

  The Journal of prosthetic dentistry 20090501

• [Risedronate for treatment of osteoporosis].

  Nihon rinsho. Japanese journal of clinical medicine 20090501

• Comparison of the effect of vitamin K(2) and risedronate on trabecular bone in glucocorticoid-treated rats: a bone histomorphometry study.

  Yonsei medical journal 20090430

• Glucocorticoid-induced osteoporosis: hope on the HORIZON.

  Lancet (London, England) 20090411

• Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.

  Lancet (London, England) 20090411

• Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20090401

• Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.

  Bone 20090401

• Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.

  The Annals of pharmacotherapy 20090401

• Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy.

  The Journal of hand surgery 20090401

• [Postmenopausal osteoporosis. Bisphosphonates are not all equal].

  MMW Fortschritte der Medizin 20090312

• [Patient compliance program aids therapy success].

  MMW Fortschritte der Medizin 20090312

• Effect of risedronate in a minipig cartilage defect model with allograft.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20090301

• Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090301

• LRP5 Polymorphisms and response to risedronate treatment in osteoporotic men.

  Calcified tissue international 20090301

• Dental implants in a patient with Paget disease under bisphosphonate treatment: a case report.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20090301

• Transcriptome and proteome analysis of osteocytes treated with nitrogen-containing bisphosphonates.

  Journal of proteome research 20090301

• Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment.

  Current osteoporosis reports 20090301

• Vitamin D status and response to treatment in post-menopausal osteoporosis.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090201

• Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.

  The American journal of medicine 20090201

• Monaural diplacusis with tinnitus, aural fullness, hyperacusis, and sensorineural hearing loss.

  Ear, nose, & throat journal 20090201

• Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.

  Clinical therapeutics 20090201

• Paget's disease 2: exploring diagnosis, management and support strategies.

  Nursing times 20090201

• Bisphosphonate therapy ameliorates hearing loss in mice lacking osteoprotegerin.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20090101

• Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.

  Rheumatology international 20090101

• The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.

  QJM : monthly journal of the Association of Physicians 20090101

• Effects of short-term risedronate on bone resorption and patient satisfaction in postmenopausal osteoporosis patients.

  Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20090101

• [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].

  Clinical calcium 20090101

• New bisphosphonates and trends in drug therapy for osteoporosis: preface.

  Clinical calcium 20090101

• [Examination of beneficial effects of risedronate in improving quality of life during long-term treatment of primary osteoporosis].

  Nihon rinsho. Japanese journal of clinical medicine 20090101

• Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study.

  Journal of bone and mineral metabolism 20090101

• Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance.

  Journal of bone and mineral metabolism 20090101

• Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis.

  PloS one 20090101

• The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.

  Journal of bone and mineral metabolism 20090101

• Heterotopic ossification in systemic sclerosis.

  Scandinavian journal of rheumatology 20090101

• Value of a new fixed-combination pack of bisphosphonate, calcium and vitamin D in the therapy of osteoporosis: results of two quantitative patient research studies.

  Drugs & aging 20090101

• Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials.

  Clinical drug investigation 20090101

• Risedronate on two consecutive days per month.

  Drugs & aging 20090101

• Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.

  Clinical interventions in aging 20090101

• The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis.

  BMC musculoskeletal disorders 20090101

• Risedronate inhibits human osteosarcoma cell invasion.

  Journal of experimental & clinical cancer research : CR 20090101

• Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection.

  Genome biology 20090101

• Prevention of hip fractures by exposure to sunlight and pharmacotherapy in patients with Alzheimer's disease.

  Aging clinical and experimental research 20090101

• Reducing hip fracture risk with risedronate in elderly women with established osteoporosis.

  Clinical interventions in aging 20090101

• Evaluation of the effect of 4 months of risedronate therapy on femoral strength using femoral strength analysis tools.

  The Journal of international medical research 20090101

• Geranylgeranyl transferase type II inhibition prevents myeloma bone disease.

  Biochemical and biophysical research communications 20081212

• Effect of temporal changes in bone turnover on the bone mineralization density distribution: a computer simulation study.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20081201

• A new dinuclear platinum complex with a nitrogen-containing geminal bisphosphonate as potential anticancer compound specifically targeted to bone tissues.

  Journal of inorganic biochemistry 20081201

• [Non traumatic tooth extraction in patients treated by bisphosphonate].

  Revue de stomatologie et de chirurgie maxillo-faciale 20081201

• Fluorescently labeled risedronate and related analogues: 'magic linker' synthesis.

  Bioconjugate chemistry 20081201

• Evaluation by digital subtraction radiography of induced changes in the bone density of the female rat mandible.

  Dento maxillo facial radiology 20081201

• Kinetic study on hemipenta hydrate risedronate monosodium in batch crystallization by cooling mode.

  International journal of pharmaceutics 20081119

• Compatibility of risedronate sodium tablets with food thickeners.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20081115

• Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo.

  Cancer research 20081101

• Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization.

  Arthritis and rheumatism 20081101

• Effects of risedronate in a rat model of osteopenia due to orchidectomy and disuse: densitometric, histomorphometric and microtomographic studies.

  Micron (Oxford, England : 1993) 20081001

• Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20081001

• Identification of material parameters based on Mohr-Coulomb failure criterion for bisphosphonate treated canine vertebral cancellous bone.

  Bone 20081001

• Cutaneous vasculitis induced by risedronate.

  Allergy 20081001

• [Efficacy and tolerability of risedronate for the treatment of osteoporosis].

  Clinical calcium 20081001

• Effects of risedronate on alveolar bone loss and angiogenesis: a stereologic study in rats.

  Journal of periodontology 20081001

• Paget disease of bone: therapeutic options.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20081001

• [Treatment of osteoporosis in the elderly: what is the evidence?].

  Tijdschrift voor gerontologie en geriatrie 20081001

• [Severe oesophagus injury as a complication during treatment with risedronic acid].

  Nederlands tijdschrift voor geneeskunde 20080927

• Monthly risedronate (Actonel) for postmenopausal osteoporosis.

  The Medical letter on drugs and therapeutics 20080908

• Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.

  Current osteoporosis reports 20080901

• IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.

  Expert review of anticancer therapy 20080901

• Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.

  The American journal of managed care 20080901

• Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment.

  Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 20080901

• Osteoporosis in men.

  The New England journal of medicine 20080821

• Osteoporosis treatment and fracture incidence: the ICARO longitudinal study.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080801

• Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors.

  Bone 20080801

• Effect of risedronate on hip structural geometry: a 1-year, double-blind trial in chemotherapy-induced postmenopausal women.

  Bone 20080801

• Effects of vitamin K(2) and risedronate on bone formation and resorption, osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid-treated rats.

  Calcified tissue international 20080801

• Maximizing effectiveness of bisphosphonate therapy for osteoporosis.

  Southern medical journal 20080801

• Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients.

  Climacteric : the journal of the International Menopause Society 20080801

• Determination of the microscopic equilibrium dissociation constants for risedronate and its analogues reveals two distinct roles for the nitrogen atom in nitrogen-containing bisphosphonate drugs.

  Journal of medicinal chemistry 20080724

• Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080701

• Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women.

  British journal of clinical pharmacology 20080701

• Effects of combined administration of alfacalcidol and risedronate on cancellous and cortical bone mass of the tibia in glucocorticoid-treated young rats.

  The Chinese journal of physiology 20080630

• Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial.

  Osteoarthritis and cartilage 20080601

• Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial.

  International journal of clinical practice 20080601

• Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080601

• Secondary osteoporosis in long-term bedridden patients with cerebral palsy.

  Pediatrics international : official journal of the Japan Pediatric Society 20080601

• Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis.

  Clinical interventions in aging 20080601

• Summaries for patients. Drug therapy for osteoporosis.

  Annals of internal medicine 20080506

• Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.

  Annals of internal medicine 20080506

• Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period.

  Annals of the rheumatic diseases 20080501

• Effects of risedronate on fracture risk in postmenopausal women with osteopenia.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080501

• Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080501

• Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.

  Bone 20080501

• Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis.

  Current medical research and opinion 20080501

• Efficacy of risedronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials.

  Current medical research and opinion 20080501

• Farnesyl pyrophosphate synthase enantiospecificity with a chiral risedronate analog, [6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl(hydroxy)methylene]bis(phosphonic acid) (NE-10501): Synthetic, structural, and modeling studies.

  Bioorganic & medicinal chemistry letters 20080501

• Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects.

  Clinical therapeutics 20080501

• Can a disorder of the vestibular system underlie an etiology for migraine?

  Ear, nose, & throat journal 20080501

• Osteoporotic fracture management in India: a survey of orthopaedic surgeons.

  Journal of the Indian Medical Association 20080501

• Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20080401

• A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.

  International journal of clinical practice 20080401

• In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications.

  Current medical research and opinion 20080401

• Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20080401

• Osteonecrosis of the jaw: new developments in an old disease.

  The Journal of rheumatology 20080401

• Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20080401

• Fracture risk remains reduced one year after discontinuation of risedronate.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080301

• Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20080301

• Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080301

• Preservation of periarticular cancellous morphology and mechanical stiffness in post-traumatic experimental osteoarthritis by antiresorptive therapy.

  Clinical biomechanics (Bristol, Avon) 20080301

• Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080301

• A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.

  Current medical research and opinion 20080301

• Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results.

  The Journal of rheumatology 20080301

• [Variance of expressions of extracellular matrix components and effects of anti-osteoporotic drugs on Mönckeberg's arteriosclerosis].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20080301

• [Radius shaft fracture in a 31-year old man].

  Revista clinica espanola 20080201

• NMR investigations of the static and dynamic structures of bisphosphonates on human bone: a molecular model.

  Journal of the American Chemical Society 20080130

• Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

  The Cochrane database of systematic reviews 20080123

• Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080101

• Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.

  Bone 20080101

• The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis.

  Journal of bone and mineral metabolism 20080101

• [Patient's preference for the daily and weekly bisphosphonate--evaluation from questionnaire of osteoporosis patients].

  Nihon rinsho. Japanese journal of clinical medicine 20080101

• Higher efficacy of urinary bone resorption marker measurements in assessing response to treatment for osteoporosis in postmenopausal women.

  The Tohoku journal of experimental medicine 20080101

• [Guide for the prevention and treatment of glucocorticoid-induced osteoporosis of the Spanish Society of Internal Medicine].

  Revista clinica espanola 20080101

• [Clinical significance of risedronate for patients with prostate cancer receiving androgen deprivation therapy].

  Nihon Hinyokika Gakkai zasshi. The japanese journal of urology 20080101

• Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.

  Clinical drug investigation 20080101

• Efficacy of risedronate in Japanese male patients with primary osteoporosis.

  Internal medicine (Tokyo, Japan) 20080101

• Additive effects of glucosamine or risedronate for the treatment of osteoarthritis of the knee combined with home exercise: a prospective randomized 18-month trial.

  Journal of bone and mineral metabolism 20080101

• Effect of risedronate on bone mass, remodelling and biomechanical strength in orchidectomized rats.

  Hormone research 20080101

• Urinary osteocalcin and other markers of bone metabolism: the effect of risedronate therapy.

  Scandinavian journal of clinical and laboratory investigation 20080101

• Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.

  Menopause (New York, N.Y.) 20080101

• Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.

  Anticancer research 20080101

• Analgesic and chondroprotective effects of risedronate in osteoarthritis assessed by electroalgometry and measurement of collagen type II fragments in urine.

  The Journal of international medical research 20080101

• [Differences among bisfosfonates--specificity of risedronate (Actonel)].

  Reumatizam 20080101

• Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system.

  BMC musculoskeletal disorders 20080101

• Medical treatment of otosclerosis: rationale for use of bisphosphonates.

  The international tinnitus journal 20080101

• Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective.

  Journal of medical economics 20080101

• Hip fractures in users of first- vs. second-generation bisphosphonates.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20071201

• Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study.

  Current medical research and opinion 20071201

• Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20071201

• Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.

  International journal of urology : official journal of the Japanese Urological Association 20071201

• Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.

  Minerva endocrinologica 20071201

• Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate.

  Journal of medicinal chemistry 20071129

• [HIP study--how to prevent hip fractures?].

  Nihon rinsho. Japanese journal of clinical medicine 20071128

• [FACT study].

  Nihon rinsho. Japanese journal of clinical medicine 20071128

• [Bisphosphonates for osteoporosis].

  Nihon rinsho. Japanese journal of clinical medicine 20071128

• [Evidence of risedronate for treatment of osteoporosis].

  Nihon rinsho. Japanese journal of clinical medicine 20071128

• [Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].

  Nihon rinsho. Japanese journal of clinical medicine 20071128

• Risedronate did not block the maximal anabolic effect of PTH in aged rats.

  Bone 20071101

• Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women.

  Current medical research and opinion 20071101

• Isoprenoid-independent pathway is involved in apoptosis induced by risedronate, a bisphosphonate, in which Bim plays a critical role in breast cancer cell line MCF-7.

  Oncology reports 20071101

• Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20071101

• Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.

  Expert opinion on pharmacotherapy 20071101

• The aminobisphosphonate risedronate preserves localized mineral and material properties of bone in the presence of glucocorticoids.

  Arthritis and rheumatism 20071101

• Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20071001

• Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.

  The journal of obstetrics and gynaecology research 20071001

• Osteoporosis: non-hormonal treatment.

  Climacteric : the journal of the International Menopause Society 20071001

• [Osteoporosis in the patients with rheumatoid arthritis (3) : the efficacy and the selection of the osteoporosis therapeutic drug].

  Clinical calcium 20071001

• Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats.

  Journal of endocrinological investigation 20071001

• Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices.

  Journal of periodontology 20070901

• Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients.

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20070901

• Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

  Clinical therapeutics 20070901

• Review of the safety and efficacy of risedronate for the treatment of male osteoporosis.

  Clinical interventions in aging 20070901

• Yearly zoledronic acid in postmenopausal osteoporosis.

  The New England journal of medicine 20070816

• Weekly risedronate in kidney transplant patients with osteopenia.

  Transplant international : official journal of the European Society for Organ Transplantation 20070801

• Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.

  Calcified tissue international 20070801

• Oral bisphosphonate associated osteonecrosis of the jaws: three case reports.

  British dental journal 20070728

• Is cortical bone hip? What determines cortical bone properties?

  Bone 20070701

• Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20070701

• [Osteoporosis treatment: choices and options].

  Polskie Archiwum Medycyny Wewnetrznej 20070701

• Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070601

• Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD).

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070601

• Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20070601

• Pharmacological treatment of osteoporosis for people over 70.

  Aging clinical and experimental research 20070601

• The futility of current approaches to chondroprotection.

  Arthritis and rheumatism 20070501

• Bisphosphonates. A cornerstone of osteoporosis treatment.

  Mayo Clinic women's healthsource 20070501

• Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading.

  Bone 20070401

• Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis.

  The Journal of clinical endocrinology and metabolism 20070401

• [Secondary osteoporosis. Evidence of treatment efficacy in patients with glucocorticoid-induced osteoporosis].

  Clinical calcium 20070401

• Additive effect of vitamin K2 and risedronate on long bone mass in hypophysectomized young rats.

  Experimental animals 20070401

• [Osteoporosis compounds in general practice. That is REAL: in routine practice the better choice].

  MMW Fortschritte der Medizin 20070329

• Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease.

  Neurology 20070320

• Effect of administration site in the gastrointestinal tract on bioavailability of poorly absorbed drugs taken after a meal.

  Journal of controlled release : official journal of the Controlled Release Society 20070312

• Risedronate for the prevention of hip fractures: concern about validity of trials.

  Archives of internal medicine 20070312

• Risedronate-induced Hepatitis.

  The American journal of medicine 20070301

• Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.

  The American journal of medicine 20070301

• Osteochemonecrosis of jaws and bisphosphonates.

  Irish medical journal 20070301

• Development and validation of a reversed-phase ion-pair high-performance liquid chromatographic method for the determination of risedronate in pharmaceutical preparations.

  Analytica chimica acta 20070212

• Differential effects of bisphosphonates on breast cancer cell lines.

  Cancer letters 20070208

• A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients.

  Rheumatology (Oxford, England) 20070201

• Effects of calcitonin, risedronate, and raloxifene on erythrocyte antioxidant enzyme activity, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis.

  Archives of medical research 20070201

• Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20070101

• Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial.

  The Journal of clinical endocrinology and metabolism 20070101

• Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20070101

• How long should patients take medications for postmenopausal osteoporosis?

  Joint, bone, spine : revue du rhumatisme 20070101

• The relationship between regional bone turnover measured using 18F-fluoride positron emission tomography and changes in BMD is equivalent to that seen for biochemical markers of bone turnover.

  Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20070101

• Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women.

  Journal of bone and mineral metabolism 20070101

• Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate.

  Journal of bone and mineral metabolism 20070101

• [The effect of risedronate treatment on bone turnover markers in patients with hip fracture].

  Acta orthopaedica et traumatologica turcica 20070101

• The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women.

  Renal failure 20070101

• Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.

  Clinical and experimental rheumatology 20070101

• Bisphosphonates and osteonecrosis of the jaw: a retrospective study.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20070101

• Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention.

  Journal of musculoskeletal & neuronal interactions 20070101

• A case of pachydermoperiostosis treated by oral administration of a bisphosphonate and arthroscopic synovectomy.

  Modern rheumatology 20070101

• Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate.

  Journal of bone and mineral metabolism 20070101

• Risedronate has no adverse effects on mouse haematopoiesis.

  Folia biologica 20070101

• Safety considerations with bisphosphonates for the treatment of osteoporosis.

  Drug safety 20070101

• Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases.

  Hormones (Athens, Greece) 20070101

• High-dose bisphosphonate therapy in an urgent case of spontaneous multiple vertebral fractures in a 55 year old woman.

  Wiener medizinische Wochenschrift (1946) 20070101

• Risedronate induced transient ocular myasthenia.

  Journal of postgraduate medicine 20070101

• Effect of bisphosphonates on nitric oxide production by inflammatory activated chondrocytes.

  Clinical and experimental rheumatology 20070101

• [Risedronate (Actonel)--from randomized clinical trials to real life].

  Reumatizam 20070101

• Dehydration of risedronate hemi-pentahydrate: analytical and physical characterization.

  Journal of pharmaceutical sciences 20061201

• European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency.

  Current medical research and opinion 20061201

• Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.

  Current medical research and opinion 20061201

• Bisphosphonates.

  Annals of the New York Academy of Sciences 20061201

• Effect of risedronate on the cortical and cancellous bone mass and mechanical properties in ovariectomized rats: a comparison with the effects of alfacalcidol.

  Journal of nutritional science and vitaminology 20061201

• [Men also need bone protection].

  MMW Fortschritte der Medizin 20061116

• [Correlation between studies and general practice].

  MMW Fortschritte der Medizin 20061116

• Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease.

  Bone 20061101

• Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia.

  Bone 20061101

• Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study.

  Arthritis and rheumatism 20061101

• [Randomized controlled trials for the prevention and treatment of glucocorticoid-induced osteoporosis].

  Clinical calcium 20061101

• Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users.

  Pharmacoepidemiology and drug safety 20061001

• Is the increase in osteoporosis prevention a result of the audit?

  Clinical neurology and neurosurgery 20061001

• Bisphosphonates activate nucleotide receptors signaling and induce the expression of Hsp90 in osteoblast-like cell lines.

  Bone 20061001

• Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate.

  Bone 20061001

• Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone.

  Bone 20061001

• Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20061001

• Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20061001

• Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20061001

• Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib.

  Calcified tissue international 20061001

• Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats.

  Experimental animals 20061001

• Beneficial effect of pretreatment and treatment continuation with risedronate and vitamin K2 on cancellous bone loss after ovariectomy in rats: a bone histomorphometry study.

  Journal of nutritional science and vitaminology 20061001

• [A young woman with headaches and skull anomalies: a long road to the diagnosis 'Paget's disease'].

  Nederlands tijdschrift voor geneeskunde 20060930

• Antioxidant effect of bisphosphonates and simvastatin on chondrocyte lipid peroxidation.

  Biochemical and biophysical research communications 20060922

• Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells.

  International journal of cancer 20060915

• Effects of a prostaglandin EP4 agonist, ONO-4819, and risedronate on trabecular microstructure and bone strength in mature ovariectomized rats.

  Bone 20060901

• Sequential treatment of ovariectomized mice with bFGF and risedronate restored trabecular bone microarchitecture and mineralization.

  Bone 20060901

• [Therapeutic effects of risedronate on Paget's disease of bone].

  Clinical calcium 20060901

• Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography.

  Bone 20060801

• Chemical makeup of microdamaged bone differs from undamaged bone.

  Bone 20060801

• Madarosis from mitochondriopathy.

  Acta ophthalmologica Scandinavica 20060801

• Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.

  The Journal of clinical endocrinology and metabolism 20060701

• Anti-inflammatory and anti-nociceptive activity of risedronate in experimental pain models in rats and mice.

  Clinical and experimental pharmacology & physiology 20060701

• Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20060701

• Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.

  Current medical research and opinion 20060701

• Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate.

  Eukaryotic cell 20060701

• Therapeutic effect of risedronate on cancellous and cortical bone in ovariectomized osteopenic rats: a comparison with the effects of alfacalcidol.

  Experimental animals 20060701

• Preventive effects of risedronate and calcitriol on cancellous osteopenia in rats treated with high-dose glucocorticoid.

  Experimental animals 20060701

• [Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].

  MMW Fortschritte der Medizin 20060622

• Long-term experience with alendronate in the treatment of osteoporosis.

  Expert opinion on pharmacotherapy 20060601

• Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.

  Southern medical journal 20060601

• Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.

  Leprosy review 20060601

• Fracture prevention in postmenopausal women.

  Clinical evidence 20060601

• The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.

  Proceedings of the National Academy of Sciences of the United States of America 20060516

• [Only bone densitometry answers this question. How stable are your patients' bones?].

  MMW Fortschritte der Medizin 20060504

• Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060501

• Between-meal risedronate does not alter bone turnover in nursing home residents.

  Journal of the American Geriatrics Society 20060501

• Osteoporosis in older people: a tale of two studies (and three treatments).

  Journal of the American Geriatrics Society 20060501

• Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.

  Current medical research and opinion 20060501

• Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.

  Maturitas 20060420

• Preventing osteoporosis-related fractures: an overview.

  The American journal of medicine 20060401

• Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis.

  Climacteric : the journal of the International Menopause Society 20060401

• Drug insight: Bisphosphonates for postmenopausal osteoporosis.

  Nature clinical practice. Endocrinology & metabolism 20060401

• Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?

  Nature clinical practice. Rheumatology 20060401

• Esophageal transit of the weekly film-coated risedronate (Actonel) placebo tablet in subjects with Kyphosis.

  International journal of pharmaceutics 20060327

• Enthalpy versus entropy-driven binding of bisphosphonates to farnesyl diphosphate synthase.

  Journal of the American Chemical Society 20060322

• Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.

  Rheumatology international 20060301

• Osteoporosis drug may protect joints.

  Health news (Waltham, Mass.) 20060301

• Osteoporosis management in a Medicaid population after the Women's Health Initiative study.

  Journal of women's health (2002) 20060301

• Potential adverse effects.

  British dental journal 20060211

• Hospitalization-related bone loss and the protective effect of risedronate.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20060201

• Pharmacological therapy of Paget's and other metabolic bone diseases.

  Bone 20060201

• Patients with hip fracture: what can be improved?

  Bone 20060201

• Strategies for the prevention and treatment of osteoporosis during early postmenopause.

  American journal of obstetrics and gynecology 20060201

• [Application of anti-resorptive drugs for the treatment of osteoporosis].

  Nihon rinsho. Japanese journal of clinical medicine 20060201

• Comparative effects of risedronate and calcitriol on cancellous bone in rats with glucocorticoid-induced osteopenia.

  Journal of nutritional science and vitaminology 20060201

• Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.

  Clinical therapeutics 20060201

• Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.

  Rheumatology international 20060101

• Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: implications for drug design.

  Proteins 20060101

• A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease.

  The American journal of gastroenterology 20060101

• Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20060101

• Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England.

  Drug safety 20060101

• Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease.

  Journal of bone and mineral metabolism 20060101

• [Your patients face the treatment of osteoporosis: How to improve the efficacy of management in clinical practice?].

  La Revue du praticien 20060101

• Bisphosphonates are effective prophylactic of early bone loss after renal transplantation.

  Transplantation proceedings 20060101

• Drug injury in the upper gastrointestinal tract: effects of alendronate.

  Gastrointestinal endoscopy clinics of North America 20060101

• Challenges of recruitment of breast cancer survivors to a randomized clinical trial for osteoporosis prevention.

  Cancer nursing 20060101

• The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20060101

• Effect of risedronate on bone metabolism after total hip arthroplasty: a prospective randomised study.

  Acta orthopaedica Belgica 20060101

• Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20060101

• Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: an approach to improving correct intake and drug adherence.

  Drugs & aging 20060101

• Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen.

  Journal of bone and mineral metabolism 20060101

• Medication persistence with weekly versus daily doses of orally administered bisphosphonates.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20060101

• A general approach for the quantitative analysis of bisphosphonates in human serum and urine by high-performance liquid chromatography/tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20060101

• Skeletal effects of short-term exposure to dexamethasone and response to risedronate treatment studied in vivo in rabbits by magnetic resonance micro-imaging and spectroscopy.

  Journal of bone and mineral metabolism 20060101

• [Biphosphonate-associated osteonecrosis of the maxilla. Case report and review of the literature].

  Schweizer Monatsschrift fur Zahnmedizin = Revue mensuelle suisse d'odonto-stomatologie = Rivista mensile svizzera di odontologia e stomatologia 20060101

• Comparative therapeutic use of Risedronate and Calcarea phosphorica--allopathy versus homeopathy--in bone repair in castrated rats.

  Brazilian oral research 20060101

• Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.

  Drug safety 20060101

• Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.

  Clinical drug investigation 20060101

• Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis.

  Advances in therapy 20060101

• [Treatment of osteoporosis by risedronate-- speed, efficacy and safety].

  Reumatizam 20060101

• Paget's disease and bisphosphonates.

  The New England journal of medicine 20051215

• Paget's disease and bisphosphonates.

  The New England journal of medicine 20051215

• [Optimizing therapy in Paget disease].

  MMW Fortschritte der Medizin 20051215

• One drug tackles two diseases.

  British dental journal 20051210

• Osteoclast responses to lipopolysaccharide, parathyroid hormone and bisphosphonates in neonatal murine calvaria analyzed by laser scanning confocal microscopy.

  The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 20051201

• Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20051201

• Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20051201

• Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20051201

• Prevention and treatment of glucocorticoid-induced osteoporosis in 2005.

  Joint, bone, spine : revue du rhumatisme 20051201

• Symptomatic hypocalcemia due to oral risedronate therapy.

  Indian journal of medical sciences 20051201

• [Examination and treatment of orthopedic-surgery patients with osteoporosis-related fragility fractures].

  Ugeskrift for laeger 20051121

• Risedronate therapy for prevention of hip fracture after stroke in elderly women.

  Neurology 20051108

• Risedronate-induced intravascular haemolysis complicated by acute tubular necrosis.

  Clinical rheumatology 20051101

• [Practical approaches to the osteoporosis treatment--instructions for drug use that draws the effect of the medicine].

  Nihon rinsho. Japanese journal of clinical medicine 20051101

• [Antiresorptive treatment after proximal femur fracture].

  Atencion primaria 20051101

• Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20051001

• Madarosis from mitochondriopathy.

  Acta ophthalmologica Scandinavica 20051001

• Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial.

  Mayo Clinic proceedings 20051001

• Review of treatment modalities for postmenopausal osteoporosis.

  Southern medical journal 20051001

• Preparation and evaluation of floating risedronate sodium-Gelucire 43/01 formulations.

  Drug development and industrial pharmacy 20051001

• Profound refractory hypocalcemia after thyroidectomy in a patient receiving chronic oral bisphosphonate therapy.

  The American surgeon 20051001

• Monitoring of Risedronate by biochemical bone markers in clinical practice.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20051001

• Effects of risedronate on trabecular microstructure and biomechanical properties in ovariectomized rat tibia.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20050901

• Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20050901

• High-dose risedronate treatment partially preserves cancellous bone mass and microarchitecture during long-term disuse.

  Bone 20050901

• Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

  The New England journal of medicine 20050901

• Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.

  Current medical research and opinion 20050901

• Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs.

  Calcified tissue international 20050901

• [Risedronate: a possible treatment for extraosseous calcification].

  Clinical calcium 20050901

• Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.

  Climacteric : the journal of the International Menopause Society 20050901

• Application of on-line Raman spectroscopy for characterizing relationships between drug hydration state and tablet physical stability.

  International journal of pharmaceutics 20050811

• Bisphosphonates stimulate an endogenous nonselective cation channel in Xenopus oocytes: potential mechanism of action.

  American journal of physiology. Cell physiology 20050801

• Alendronate (Fosamax) and risedronate (Actonel) revisited.

  Obstetrics and gynecology 20050801

• The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial.

  Archives of internal medicine 20050801

• Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke.

  Archives of internal medicine 20050801

• The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover.

  Bone 20050701

• The use of bisphosphonates in the treatment of osteoporosis.

  Current opinion in rheumatology 20050701

• Risedronate induced BOOP complicated with sarcoidosis.

  Thorax 20050701

• Chronic diffuse sclerosing osteomyelitis treated with risedronate.

  The Journal of rheumatology 20050701

• Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study.

  Journal of periodontology 20050701

• Involvement of Ras/extracellular signal-regulated kinase, but not Akt pathway in risedronate-induced apoptosis of U937 cells and its suppression by cytochalasin B.

  Biochemical pharmacology 20050615

• Risedronate in the treatment of Murine Chagas' disease.

  Parasitology research 20050601

• A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.

  Health technology assessment (Winchester, England) 20050601

• Microcracks in cortical bone: how do they affect bone biology?

  Current osteoporosis reports 20050601

• A bright future for osteoporosis treatment.

  Drug news & perspectives 20050601

• [Marketing--alendronate versus risedronate].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20050519

• [To increase bone density faster and stronger].

  MMW Fortschritte der Medizin 20050505

• Current pharmacological treatment for fibrous dysplasia and perspectives for the future.

  Joint, bone, spine : revue du rhumatisme 20050501

• Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women.

  European journal of obstetrics, gynecology, and reproductive biology 20050501

• Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20050501

• Alendronate (Fosamax) and risedronate (Actonel) revisited.

  The Medical letter on drugs and therapeutics 20050425

• [Paget's disease and its therapeutic management].

  Presse medicale (Paris, France : 1983) 20050423

• [Calcium gaps in osteoporosis patients close. Blister pack simplifies comedication of calcium and bisphosphonates].

  MMW Fortschritte der Medizin 20050407

• [Excellent adjustment with greater action. To pay attention to improving compliance].

  MMW Fortschritte der Medizin 20050407

• Structural and analytical characterization of three hydrates and an anhydrate form of risedronate.

  Journal of pharmaceutical sciences 20050401

• Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data.

  Aging clinical and experimental research 20050401

• Bisphosphonates induce inflammation and rupture of atherosclerotic plaques in apolipoprotein-E null mice.

  Biochemical and biophysical research communications 20050318

• Risedronate therapy for prevention of hip fracture after stroke in elderly women.

  Neurology 20050308

• Oral antiresorptive therapy.

  Current rheumatology reports 20050301

• Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment.

  Bone 20050301

• Risedronate for prevention and treatment of osteoporosis in postmenopausal women.

  Expert opinion on pharmacotherapy 20050301

• Glucocorticoid-induced osteoporosis: treatment options and guidelines.

  Current osteoporosis reports 20050301

• [Pharmacological treatment of osteitis deformans (Paget's bone disease)].

  Ugeskrift for laeger 20050227

• [Evaluation of the effects of treatment of osteoporosis].

  Ugeskrift for laeger 20050227

• [Osteoporosis in the elderly--diagnosis and treatment].

  MMW Fortschritte der Medizin 20050217

• Alendronate and risedronate: reports of severe bone, joint, and muscle pain.

  Archives of internal medicine 20050214

• The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study.

  Bone 20050201

• [FACT study: benefits of alendronate].

  MMW Fortschritte der Medizin 20050113

• Extemporaneous procedures for dissolving risedronate tablets for oral administration and for feeding tubes.

  The Annals of pharmacotherapy 20050101

• Trochanteric hip fracture in an elderly patient with leprosy during osteoporosis treatment with risedronate and alfacalcidol.

  Journal of bone and mineral metabolism 20050101

• Long-term disuse osteoporosis seems less sensitive to bisphosphonate treatment than other osteoporosis.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20050101

• Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20050101

• Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.

  Treatments in endocrinology 20050101

• Interleukin-18 (IL-18) and matrix metalloproteinase-9 (MMP-9) in post-menopausal osteoporosis.

  Archives of gerontology and geriatrics 20050101

• Structure-activity relationships of a new class of aromatic bisphosphonates that inhibit tumor cell proliferation in vitro.

  Anticancer research 20050101

• Chondrosarcoma in Paget's disease of bone.

  Clinical and experimental rheumatology 20050101

• Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173].

  Arthritis research & therapy 20050101

• Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis.

  Treatments in endocrinology 20050101

• Systemic effects of fluticasone nasal spray: report of 2 cases.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20050101

• Effects of risedronate on femoral bone mineral density and bone strength in sciatic neurectomized young rats.

  Journal of bone and mineral metabolism 20050101

• Periodontal assessment of postmenopausal women receiving risedronate.

  Menopause (New York, N.Y.) 20050101

• Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20050101

• [What do we need to know--what can we do?].

  Krankenpflege Journal 20050101

• Seven years of treatment with risedronate in women with postmenopausal osteoporosis.

  Calcified tissue international 20041201

• Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.

  Calcified tissue international 20041201

• Pharmaceutical care and community pharmacists' understanding of bisphosphonate dosing information.

  Journal of clinical pharmacy and therapeutics 20041201

• Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.

  Current medical research and opinion 20041201

• Oral antiresorptive therapy.

  Current osteoporosis reports 20041201

• Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20041101

• Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.

  Journal of the American Geriatrics Society 20041101

• Pharmacologic prevention of osteoporotic fractures.

  American family physician 20041001

• Treating osteoporosis in post-menopausal women: a case approach.

  Cleveland Clinic journal of medicine 20041001

• New treatments for brittle bones.

  Annals of internal medicine 20040907

• Coming to grips with bone loss.

  Science (New York, N.Y.) 20040903

• Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.

  Calcified tissue international 20040901

• Antiresorptive therapy conserves some periarticular bone and ligament mechanical properties after anterior cruciate ligament disruption in the rabbit knee.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20040901

• Fracture protection in osteoporosis with risedronate.

  Hospital medicine (London, England : 1998) 20040901

• [Weekly Fosamax tablet is significantly more effective than risedronate daily, as results of the Head-to-Head Study show].

  Praxis 20040901

• Preparation and evaluation of floating risedronate sodium Gelucire 39/01 matrices.

  Acta pharmaceutica (Zagreb, Croatia) 20040901

• [Stability also depends on other parameters. Bone density--not a good indicator for fracture prevention].

  MMW Fortschritte der Medizin 20040805

• [Are there differences in bisphosphonates? (interview by Dr. Beate Schumacher)].

  MMW Fortschritte der Medizin 20040805

• Osteoblast proliferation and maturation by bisphosphonates.

  Biomaterials 20040801

• The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits.

  Bone 20040801

• Effects of risedronate on bone density in anorexia nervosa.

  The Journal of clinical endocrinology and metabolism 20040801

• Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.

  Current oncology reports 20040701

• Prevention of glucocorticoid-induced osteoporosis.

  Southern medical journal 20040601

• [Faster and long-lasting protection with risedronate. With strengthened bones longer self-sufficient].

  MMW Fortschritte der Medizin 20040527

• [Risedronate affects bone strength, too. Faster protective effect on microarchitecture].

  MMW Fortschritte der Medizin 20040527

• [Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?].

  MMW Fortschritte der Medizin 20040520

• Mucosal irritative and healing impairment action of risedronate in rat stomachs: comparison with alendronate.

  Journal of gastroenterology and hepatology 20040501

• Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20040501

• Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis.

  Current medical research and opinion 20040501

• Contribution of Complementarity-Determining Region 3 of the T-Cell Receptor Vδ2 Chain to the Recognition of Aminobisphosphonates by Human γδ T-Cells.

  International journal of hematology 20040501

• [Bone quality in treatment with raroxifene ].

  Clinical calcium 20040501

• Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography.

  Bone 20040401

• Efficacy of risedronate on clinical vertebral fractures within six months.

  Current medical research and opinion 20040401

• Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi.

  International journal of antimicrobial agents 20040301

• Antiparasitic activity of risedronate in a murine model of acute Chagas' disease.

  International journal of antimicrobial agents 20040301

• [Data comparison of osteoporosis patients demonstrates nasal administration is not optimal].

  MMW Fortschritte der Medizin 20040212

• Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.

  Calcified tissue international 20040201

• An update on bisphosphonates.

  Current rheumatology reports 20040201

• Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20040201

• [New guideline for the treatment of osteoporosis].

  Nihon rinsho. Japanese journal of clinical medicine 20040201

• [Risedronate treatment for osteoporosis].

  Nihon rinsho. Japanese journal of clinical medicine 20040201

• [VERT(Vertebral Efficacy with Risedronate Therapy)-MN(Multinational) Study and VERT-NA(North America) Study].

  Nihon rinsho. Japanese journal of clinical medicine 20040201

• [Combination therapy of bisphosphonate and estrogen for osteoporosis].

  Nihon rinsho. Japanese journal of clinical medicine 20040201

• The effects of binge alcohol exposure on bone resorption and biomechanical and structural properties are offset by concurrent bisphosphonate treatment.

  Alcoholism, clinical and experimental research 20040101

• Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies.

  Journal of bone and mineral metabolism 20040101

• Clinical trial of risedronate in Japanese volunteers: a study on the effects of timing of dosing on absorption.

  Journal of bone and mineral metabolism 20040101

• Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database.

  Journal of managed care pharmacy : JMCP 20040101

• Parathyroid hormone.

  The Journal of the American Academy of Orthopaedic Surgeons 20040101

• Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study.

  European review for medical and pharmacological sciences 20040101

• Markers of bone resorption in bisphosphonate therapy of Paget's disease.

  Clinical and experimental rheumatology 20040101

• [Consistent therapeutic success in osteoporosis].

  Krankenpflege Journal 20040101

• Regulation of mineral-to-matrix ratio of lumbar trabecular bone in ovariectomized rats treated with risedronate in combination with or without vitamin K2.

  Journal of bone and mineral metabolism 20040101

• A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial.

  Journal of bone and mineral metabolism 20040101

• Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk.

  Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20040101

• Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations.

  MedGenMed : Medscape general medicine 20040101

• Health-economic comparison of three recommended drugs for the treatment of osteoporosis.

  International journal of clinical pharmacology research 20040101

• [Update 2004. Osteoporosis--management--current status].

  Krankenpflege Journal 20040101

• [Routine osteoporosis therapy].

  Krankenpflege Journal 20040101

• Skeletal benefit after one year of risedronate therapy in patients with rheumatoid arthritis and glucocorticoid-induced osteoporosis: a prospective study.

  International journal of clinical pharmacology research 20040101

• Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption.

  Endocrinology 20031201

• Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20031201

• Spectrophotometric determination of some drugs for osteoporosis.

  Chemical & pharmaceutical bulletin 20031201

• A prospective study of risedronate on regional bone metabolism and blood flow at the lumbar spine measured by 18F-fluoride positron emission tomography.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20031201

• Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs.

  Bone 20031201

• Patent news.

  IDrugs : the investigational drugs journal 20031201

• An approach to postmenopausal osteoporosis treatment: a case study review.

  Journal of the American Academy of Nurse Practitioners 20031201

• Osteoporosis management in the new millennium.

  Primary care 20031201

• Use of highly potent bisphosphonates in the treatment of osteoporosis.

  Current osteoporosis reports 20031201

• Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography.

  Calcified tissue international 20031101

• Aging bone and osteoporosis: strategies for preventing fractures in the elderly.

  Archives of internal medicine 20031013

• Determination of risedronate in human urine by column-switching ion-pair high-performance liquid chromatography with ultraviolet detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030825

• [Evidence-based therapy of osteoporosis--comment on DMW 17/2003].

  Deutsche medizinische Wochenschrift (1946) 20030725

• Bisphosphonates: new indications and methods of administration.

  Current opinion in rheumatology 20030701

• Show us the numbers.

  Canadian family physician Medecin de famille canadien 20030701

• [Therapy of osteoporosis with bisphosphonate. Bone quality maintained over years].

  MMW Fortschritte der Medizin 20030605

• Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20030601

• Identifying the osteopenic patient and preventing worsening of the disease.

  Current women's health reports 20030601

• Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20030601

• Canine cancellous bone microarchitecture after one year of high-dose bisphosphonates.

  Calcified tissue international 20030601

• [To treat effectively without delay. The data on fractures decisive].

  MMW Fortschritte der Medizin 20030522

• [For patients with osteoporosis-induced fracture the emergency brake must be pulled. Every 4th patient as a recurrence in the following year].

  MMW Fortschritte der Medizin 20030508

• Tolerability and compliance with risedronate in clinical practice.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20030501

• A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20030501

• [Osteoporosis in men].

  Deutsche medizinische Wochenschrift (1946) 20030425

• Involvement of vacuolar H+ -ATPase in incorporation of risedronate into osteoclasts.

  Bone 20030401

• Canadian consensus on osteoporosis. Preventing osteoporosis among postmenopausal women.

  Canadian family physician Medecin de famille canadien 20030401

• [Osteoporosis therapy. Bisphosphonates compared].

  MMW Fortschritte der Medizin 20030327

• [Vertebral body fracture as incidental finding in thoracic radiography. Family physician usually does not learn about it].

  MMW Fortschritte der Medizin 20030220

• Effects of risedronate, alendronate, and etidronate on the viability and activity of rat bone marrow stromal cells in vitro.

  Calcified tissue international 20030201

• Editorial: greater risk, greater benefit--true or false?

  The Journal of clinical endocrinology and metabolism 20030201

• Risedronate prevents new vertebral fractures in postmenopausal women at high risk.

  The Journal of clinical endocrinology and metabolism 20030201

• Three hydrates of the bisphosphonate risedronate, consisting of one molecular and two ionic structures.

  Acta crystallographica. Section C, Crystal structure communications 20030201

• [Effects of bisphosphonate on trabecular microstructure].

  Nihon rinsho. Japanese journal of clinical medicine 20030201

• [Risedronate].

  Nihon rinsho. Japanese journal of clinical medicine 20030201

• [Treatment of osteoporosis provided from the orthopaedic surgeon's standpoint].

  Nihon rinsho. Japanese journal of clinical medicine 20030201

• Role of gastric mucosal and gastric juice cytokine concentrations in development of bisphosphonate damage to gastric mucosa.

  Digestive diseases and sciences 20030201

• [Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective].

  Lakartidningen 20030109

• Bone density changes with once weekly risedronate in postmenopausal women.

  Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20030101

• Therapeutic options: an evidence-based approach to prevention and treatment of osteoporosis.

  International journal of fertility and women's medicine 20030101

• Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.

  Current medical research and opinion 20030101

• Risedronate for the prevention and treatment of postmenopausal osteoporosis.

  The Cochrane database of systematic reviews 20030101

• [Bisphosphonates in the prevention of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis].

  Reumatizam 20030101

• Pharmacoeconomic analysis of osteoporosis treatment with risedronate.

  International journal of clinical pharmacology research 20030101

• Risedronate once a week.

  Treatments in endocrinology 20030101

• A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20021201

• Medications for postmenopausal osteoporosis prevention.

  Harvard women's health watch 20021201

• Risedronate prevents hip fractures, but who should get therapy?

  Cleveland Clinic journal of medicine 20021201

• [Osteoporosis].

  Der Internist 20021201

• Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.

  Cancer research 20021115

• Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis.

  Bone 20021101

• [Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate].

  MMW Fortschritte der Medizin 20021031

• Once-a-week risedronate (actonel).

  The Medical letter on drugs and therapeutics 20021014

• Bisphosphonates and the upper gastrointestinal tract: skeletal gain without visceral pain?

  Mayo Clinic proceedings 20021001

• [Treatment of osteoporosis. Not only measurements count].

  MMW Fortschritte der Medizin 20020905

• 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.

  The Journal of rheumatology 20020901

• Bisphosphonates.

  Maturitas 20020830

• Commentary on: Bone mineral density and fracture prevalence in long-term kidney graft recipients.

  Transplantation 20020827

• The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.

  Calcified tissue international 20020801

• Prevention of bone loss in ovariectomized rats by combined treatment with risedronate and 1alpha,25-dihydroxyvitamin D3.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20020801

• What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates.

  Digestive diseases and sciences 20020801

• Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis.

  Endocrine reviews 20020801

• Osteoporosis in elderly: prevention and treatment.

  Clinics in geriatric medicine 20020801

• [Osteoporosis therapy. A comparison of bisphosphonates].

  MMW Fortschritte der Medizin 20020711

• Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats.

  Endocrinology 20020701

• Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20020701

• Bone quality: getting closer to a definition.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20020701

• Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study.

  Regulatory toxicology and pharmacology : RTP 20020601

• Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20020528

• The cost utility of bisphosphonate treatment in established osteoporosis.

  QJM : monthly journal of the Association of Physicians 20020501

• Risedronate: a new oral bisphosphonate.

  Clinical therapeutics 20020501

• [Episcleritis secondary to risedronate].

  Medicina clinica 20020427

• [When osteoporosis first manifests itself. Without therapy the next fracture threatens].

  MMW Fortschritte der Medizin 20020404

• Risedronate for the prevention of fractures in postmenopausal osteoporosis.

  The Annals of pharmacotherapy 20020401

• [Risedronate, a new diphosphonate in osteoporosis and Paget's disease].

  Presse medicale (Paris, France : 1983) 20020302

• Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials.

  Mayo Clinic proceedings 20020301

• Risedronate for the prevention and treatment of corticosteroid-induced osteoporosis.

  The Annals of pharmacotherapy 20020301

• [Risedronate: clinical usage].

  Nihon rinsho. Japanese journal of clinical medicine 20020301

• The underuse of therapy in the secondary prevention of hip fractures.

  Drugs & aging 20020101

• Risedronate reduces the risk of first vertebral fracture in osteoporotic women.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20020101

• Response of bone mineral density to once-weekly administration of risedronate.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20020101

• Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity.

  Reviews in gastroenterological disorders 20020101

• Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review.

  Drug safety 20020101

• A review of combination regimens for osteoporosis--prevention and treatment.

  International journal of fertility and women's medicine 20020101

• [Osteoporosis: diagnosis, prevention and treatment].

  Medicina (Kaunas, Lithuania) 20020101

• [Osteoporosis: diagnosis and treatment of vertebral fractures].

  Medicina (Kaunas, Lithuania) 20020101

• Prevention and treatment of osteoporosis.

  Clinical cornerstone 20020101

• [Therapy of osteoporosis. Risk factors alone are not an indication].

  MMW Fortschritte der Medizin 20011206

• Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.

  Bone 20011201

• Review of risedronate in the treatment of osteoporosis.

  Expert opinion on pharmacotherapy 20011201

• Risedronate for the prevention and treatment of postmenopausal osteoporosis: results from recent clinical trials.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20011201

• [Economic aspects of osteoporosis therapy. What does a prevented fracture cost?].

  MMW Fortschritte der Medizin 20011122

• A method to assess the proportion of treatment effect explained by a surrogate endpoint.

  Statistics in medicine 20011115

• Role of alendronate and risedronate in preventing and treating osteoporosis.

  Cleveland Clinic journal of medicine 20011101

• Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage.

  Calcified tissue international 20011101

• [Alternatives to hormonal treatment for the prevention of postmenopausal osteoporosis: the bisphosphonates].

  Gynecologie, obstetrique & fertilite 20011101

• [Osteoporosis. Fracture as alarm signal].

  MMW Fortschritte der Medizin 20011011

• Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH.

  Bone 20011001

• Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.

  Calcified tissue international 20011001

• Tolerability of risedronate in postmenopausal women intolerant of alendronate.

  Aging (Milan, Italy) 20011001

• Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase.

  The Journal of biological chemistry 20010907

• [Optimizing treatment of osteoporosis. Rapidly effective therapy lowers fracture risk in 1 year up to 70%].

  MMW Fortschritte der Medizin 20010906

• [Risedronate now also approved for hip fractures. Study discloses significant risk reduction in proximal femoral neck fractures].

  MMW Fortschritte der Medizin 20010906

• Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.

  Blood 20010901

• Pharmacologic therapy for the treatment and prevention of osteoporosis.

  The Nursing clinics of North America 20010901

• Bisphosphonates for osteoporosis.

  Drug and therapeutics bulletin 20010901

• Risedronate: a new oral bisphosphonate.

  Clinical therapeutics 20010901

• Osteoporosis in children and adolescent girls: case report of idiopathic juvenile osteoporosis and review of the literature.

  Obstetrical & gynecological survey 20010801

• The in-vitro porcine adhesion model is not predictive of the esophageal transit of risedronate tablets in humans.

  International journal of pharmaceutics 20010717

• The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water.

  International journal of pharmaceutics 20010717

• [Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].

  Nederlands tijdschrift voor geneeskunde 20010714

• [Fluorides and bisphosphonates in the treatment of osteoporosis].

  Der Orthopade 20010701

• (31)P NMR of apicomplexans and the effects of risedronate on Cryptosporidium parvum growth.

  Biochemical and biophysical research communications 20010615

• Osteoporosis in men.

  American family physician 20010615

• Re: Lanza et al.--Endoscopic comparison of alendronate and risedronate.

  The American journal of gastroenterology 20010601

• The effect of risedronate on the risk of hip fracture in elderly women.

  The New England journal of medicine 20010531

• The effect of risedronate on the risk of hip fracture in elderly women.

  The New England journal of medicine 20010531

• The effect of risedronate on the risk of hip fracture in elderly women.

  The New England journal of medicine 20010531

• Absolute vs. relative numbers in evaluating drug therapy.

  American family physician 20010515

• [Bisphosphonates in osteoporosis. Significantly reduces risk of fracture].

  MMW Fortschritte der Medizin 20010503

• The role of combination treatment for osteoporosis.

  The Journal of clinical endocrinology and metabolism 20010501

• Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.

  The Journal of clinical endocrinology and metabolism 20010501

• Risedronate: clinical usage.

  International journal of clinical practice 20010501

• Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000.

  Clinical therapeutics 20010401

• Once-a-week alendronate (Fosamax).

  The Medical letter on drugs and therapeutics 20010319

• Maintenance of cortical bone in human parathyroid hormone(1-84)-treated ovariectomized rats.

  Bone 20010301

• Hip fractures: do preventive drugs work for all?

  Health news (Waltham, Mass.) 20010301

• Evidence-based medicine: putting theory into practice.

  Hospital medicine (London, England : 1998) 20010301

• Risedronate: a clinical review.

  Archives of internal medicine 20010212

• Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

  The New England journal of medicine 20010201

• Treatment of osteoporosis with bisphosphonates.

  Rheumatic diseases clinics of North America 20010201

• Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration.

  Pharmaceutical research 20010201

• Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastro-oesophageal reflux disease and normal control subjects.

  Alimentary pharmacology & therapeutics 20010101

• Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis.

  Bone 20010101

• Risedronate increases bone mineral density and reduces the vertebral fracture incidence in postmenopausal women.

  Clinical and experimental rheumatology 20010101

• Prevention and treatment of osteoporosis.

  Clinical medicine (London, England) 20010101

• Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.

  Drugs 20010101

• Risedronate treatment and extended fracture protection in postmenopausal women.

  Clinical and experimental rheumatology 20010101

• Osteoporosis in men.

  Orthopedic nursing 20010101

• Comparison insight dual X-ray absorptiometry (DXA), histomorphometry, ash weight, and morphometric indices for bone evaluation in an animal model (the orchidectomized rat) of male osteoporosis.

  Calcified tissue international 20010101

• [Patients with fractures are in the front line for osteoporosis treatment but how to treat?].

  Duodecim; laaketieteellinen aikakauskirja 20010101

• Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 19980401

• Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.

  The Journal of clinical endocrinology and metabolism